Company profile: Calidi Biotherapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage cancer immunotherapies based on stem cell-delivered oncolytic viruses. Programs include NeuroNova (neural stem cells + oncolytic adenovirus) for glioblastoma; SuperNova (adipose-derived mesenchymal stem cells + oncolytic vaccinia) for advanced solid tumors; RTNova, a systemic enveloped oncolytic virotherapy; CLD-101 in Phase 1 for recurrent high-grade glioma; and CLD-201, a cell-based virotherapy planned for Phase 1.
Products and services
- NeuroNova (NNV): Neural stem cell-based therapy delivering an oncolytic adenovirus to glioblastoma tumor sites, engineered to attack aggressive brain or spinal cord cancers
- SuperNova (SNV): Adipose-derived mesenchymal stem cells loaded with oncolytic vaccinia virus to treat advanced solid tumors, constructed for cell-based transport of an oncolytic vaccinia payload to tumor targets
- RTNova: Systemic enveloped oncolytic virotherapy designed to target all tumor sites across the body, engineered to reach and affect tumors wherever they occur
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Calidi Biotherapeutics
Senesco Technologies
HQ: United States
Website
- Description: Provider of biotech research and development focused on cancer therapeutics and plant gene research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Senesco Technologies company profile →
Affimed
HQ: Germany
Website
- Description: Provider of innate cell engager (ICE) antibody therapeutics for cancer, including AFM13 (CD30/CD16A), AFM24 (EGFR-directed engaging NK cells and macrophages), and AFM28 (CD123/CD16A for AML), plus the ROCK platform for customizable ICEs, ongoing clinical trials, and partnerships with pharmaceutical companies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Affimed company profile →
BriaCell Therapeutics
HQ: United States
Website
- Description: Provider of immuno-oncology therapeutics developing targeted approaches for cancer management, including Bria-IMT™, a cell-based immunotherapy for advanced metastatic breast cancer that stimulates the immune system to target and kill cancer cells, and Bria-OTS™, a personalized off-the-shelf immunotherapy for advanced breast cancer engineered to match patients' HLA types.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BriaCell Therapeutics company profile →
Morphotek
HQ: United States
Website
- Description: Provider of gene evolution-based monoclonal antibody products to treat cancer, inflammation, and infectious diseases. Offerings include RESPECT-H+L conjugation technology enabling dual payload delivery with in vivo ADC tracking, and an Eribulin ADC payload with cytotoxic effects on receptor-positive and neighboring receptor-negative tumor cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Morphotek company profile →
Apeiron Biologics
HQ: Austria
Website
- Description: Provider of discovery and development of novel cancer immunotherapies, with products including Qarziba (cancer immunotherapy, licensed to EUSAPharma), APN401 (first-in-class autologous cell therapy inhibiting the immune checkpoint Cbl-b using RNAi to treat solid tumors), and APN01 (inhaled treatment in clinical trials targeting SARS-CoV-2 in the respiratory tract).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apeiron Biologics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Calidi Biotherapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Calidi Biotherapeutics
2.2 - Growth funds investing in similar companies to Calidi Biotherapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Calidi Biotherapeutics
4.2 - Public trading comparable groups for Calidi Biotherapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →